, to test the hypothesis that D 1 -and D 2 -like receptors interact to inhibit renal sodium transport in vivo in anesthetized rats. Increasing doses of Z-1046, administered via the right renal artery, increased renal blood flow (RBF), urine flow, and absolute and fractional sodium excretion without affecting glomerular filtration rate. For determination of the dopamine receptor involved in the renal functional effects of Z-1046, another group of rats received Z-1046 at 2 µg · kg Ϫ1 · min Ϫ1 (n ϭ 10) in the presence or absence of the D 2 -like receptor antagonist domperidone and/or the D 1 -like antagonist SCH-23390. Domperidone alone had no effect but blocked the Z-1046-mediated increase in urine flow and sodium excretion; it enhanced the increase in RBF after Z-1046. SCH-23390 by itself decreased urine flow and sodium excretion without affecting RBF and blocked the diuretic, natriuretic, and renal vasodilatory effect of Z-1046. We conclude that the renal vasodilatory effect of Z-1046 is D 1 -like receptor dependent, whereas the diuretic and natriuretic effects are both D 1 -and D 2 -like receptor dependent. dopamine receptors; sodium excretion; renal hemodynamics DOPAMINE IS AN ENDOGENOUS catecholamine that modulates many cellular activities, including behavior, hormone synthesis and release, blood pressure, and transmembrane ion transport (22, 23, 37 (8, 15, 16, 26, 27, 32, 43, 45) . Most studies in vivo have shown that the natriuretic effect of dopamine is exerted mainly via D 1 -like receptors (reviewed in Ref. 23). The effect of D 2 -like receptors, independent of D 1 -like receptors, on tubular function remains to be settled. In anesthetized rats, bromocriptine, a D 2 -like agonist, has been reported to increase renal blood flow (RBF) and superficial nephron glomerular filtration rate (GFR) without affecting urinary sodium excretion (35, 40) . However, in conscious, chronically catheterized dogs, the intrarenal administration of the D 2 -like receptor agonist quinpirole produced significant dose-dependent antidiuresis and antinatriuresis accompanied by a decrease in GFR, renal plasma flow, and sodium excretion (39). In agreement with the quinpirole data, in a similar preparation in dogs, the D 2 antagonist YM-09151 increased sodium excretion, an effect that was blocked by the D 2 -like agonist quinpirole (38). In the isolated perfused kidney, haloperidol, a D 2 -like antagonist, also increased sodium excretion (2), and in the anesthetized rat, the antinatriuretic effect of the D 1 -like antagonist SCH-23390 was reversed by the D 2 antagonist YM-09151 (12). These results indicate that D 2 -like receptors exert an effect on sodium excretion opposite to that of D 1 -like receptors.
D 1 -and D 2 -like receptors also have been shown to interact with other signaling pathways and effector proteins, including potassium and calcium channels, phosphatidylinositol metabolism, and arachidonic acid release (22, 23, 37) .
Pharmacological, biochemical, and molecular evidence also points to the existence of D 1 -and D 2 -like receptors in the kidney. Thus the D 1A , D 1B , D 2 Long , D 3 , and D 4 receptor genes are expressed in specific nephron segments and in kidney cell lines (8, 15, 16, 26, 27, 32, 43, 45) . Most studies in vivo have shown that the natriuretic effect of dopamine is exerted mainly via D 1 -like receptors (reviewed in Ref. 23 ). The effect of D 2 -like receptors, independent of D 1 -like receptors, on tubular function remains to be settled. In anesthetized rats, bromocriptine, a D 2 -like agonist, has been reported to increase renal blood flow (RBF) and superficial nephron glomerular filtration rate (GFR) without affecting urinary sodium excretion (35, 40) . However, in conscious, chronically catheterized dogs, the intrarenal administration of the D 2 -like receptor agonist quinpirole produced significant dose-dependent antidiuresis and antinatriuresis accompanied by a decrease in GFR, renal plasma flow, and sodium excretion (39) . In agreement with the quinpirole data, in a similar preparation in dogs, the D 2 antagonist YM-09151 increased sodium excretion, an effect that was blocked by the D 2 -like agonist quinpirole (38) . In the isolated perfused kidney, haloperidol, a D 2 -like antagonist, also increased sodium excretion (2) , and in the anesthetized rat, the antinatriuretic effect of the D 1 -like antagonist SCH-23390 was reversed by the D 2 antagonist YM-09151 (12) . These results indicate that D 2 -like receptors exert an effect on sodium excretion opposite to that of D 1 -like receptors.
Dopamine influences sodium transport by regulation of Na ϩ /H ϩ exchanger (NHE) activity in brush border membranes and Na ϩ -K ϩ -ATPase activity in basolateral membranes (3, 7, 33) . D 1 -like receptors inhibit NHE activity, whereas D 2 -like receptors may increase its activity (23) . The effect of dopamine receptor subtypes on Na ϩ -K ϩ -ATPase is controversial. For example, D 1 -like receptors, independent of D 2 -like receptors, inhibit the sodium pump, whereas the D 2 -like agonist bromocriptine has been shown to stimulate Na ϩ -K ϩ -ATPase activity in renal proximal tubule cells (20) . The ability of D 2 -like receptors to stimulate sodium transport is, at first glance, at variance with the reports of Bertorello and Aperia (3) and Satoh et al. (33) . These investigators reported that D 2 -like receptors, in concert with D 1 -like receptors, inhibited Na ϩ -K ϩ -ATPase activity in renal proximal tubules and neuronal cells (3, 4, 33) . In the LTK Ϫ cell transfected with either the rat D 1A or D 2 Long cDNA, it was found that D 1 -like receptor stimulation decreased Na ϩ -K ϩ -ATPase activity, whereas D 2 -like receptor stimulation produced the opposite effect; these effects were transduced by increases or decreases in cAMP production, respectively (18, 44) . However, in the LTK Ϫ cell transfected with both rat D 1A and D 2 Long cDNA, D 2 -like agonists enhanced the ability of D 1 -like agonists to stimulate cAMP production (42) . In heterologously transfected Chinese hamster ovary (CHO) cells expressing 10 times more D 2 than D 1 receptors, stimulation of either receptor resulted in a potentiation of arachidonic acid release compared with those cells expressing only one receptor (30) . Although neither the D 1 nor the D 2 receptor alone stimulated arachidonic acid, dopamine and other G i -coupled receptors amplified ATP receptor-stimulated arachidonic acid release (9, 24) . Arachidonic acid cytochrome P-450 products have been shown to inhibit renal sodium transport (21, 28) . Both protein kinase A and protein kinase C are involved in the transduction of dopamine-mediated arachidonic acid release (9, 25) . It is of interest that D 1 -like receptors increase renal phospholipase C and protein kinase C activity (11, 24) . Thus D 1 -D 2 synergism in the production of cAMP, phosphoinositide, and arachidonic acid products may explain the synergism of D 1 -like and D 2 -like agonists in their inhibition of Na ϩ -K ϩ -ATPase activity.
The effect on sodium excretion of the interaction between a D 1 -and D 2 -like agonist has not been studied in vivo, due in part to the lack of availability of a drug that is selective to D 1 -and D 2 -like receptor subtypes without affinity to adrenergic or serotonergic receptors. This limitation has been overcome with the availability of Z-1046, a dopaminergic agonist with rank-order potency in transfected CHO cells of (34) . In these transfected cells, the inhibition constants for the D 1 -like receptors assessed by [ 3 H]SCH-23390 binding were 25.4 Ϯ 9.3 nM for D 1 and 11.9 Ϯ 9.3 for D 5 (corresponding values for dopamine were much higher: D 1 ϭ 1199 Ϯ 137.6 nM and D 5 ϭ 312 Ϯ 37.2 nM). The inhibition constants for D 2 -like receptors assessed by [ 3 H]spiperone binding were 9.9 Ϯ 3.9 nM for D 2 , 0.7 Ϯ 0.1 nM for D 3 , and 1.9 Ϯ 0.6 nM for D 4 [corresponding values for dopamine were much higher (D 2 ϭ 4970 Ϯ 871 nM, D 3 ϭ 58.1 Ϯ 2.8 nM, and D 4 ϭ 123.7 Ϯ 31 nM)]. It must be pointed out that the high inhibition constants for dopamine are close to the concentrations of dopamine found in renal proximal tubule lumen and urine (17, 23) . Z-1046 had no agonist effect on either ␤ 1 -or ␤ 2 -adrenergic, ␣ 1 -adrenergic, or 5-hydroxytryptamine 2 receptors but had an ␣ 1 -adrenergic receptor antagonist effect (unlike dopamine, which is an agonist at ␣ 1 -adrenergic receptors) (13, 17) . Z-1046 also has an ␣ 2 -adrenergic agonist activity (comparable to dopamine), which was assessed by inhibition of electrically induced tachycardia in guinea pig atria (17, 34) . We therefore tested, using Z-1046, the hypothesis that D 1 -and D 2 -like receptors interact to inhibit renal sodium transport in vivo. We determined the effect of Z-1046 on various parameters of renal function, including RBF, GFR, urine flow (V) and absolute Values are means Ϯ SE; n ϭ 6 Wistar-Kyoto (WKY) rats (347 Ϯ 7 g body wt). MAP, mean arterial pressure; RBF, renal blood flow; GFR, glomerular filtration rate; V, urine flow; U Na V, absolute sodium excretion; FE Na , fractional sodium excretion; C, control period. (U Na V) and fractional (FE Na ) sodium excretion. The role of D 2 -like receptors was determined by the use of the D 2 -like antagonist domperidone, which is devoid of central nervous system effects (41) . The role of D 1 -like receptors was determined by the use of the D 1 -like antagonist SCH-23390 (22) . To minimize confounding systemic effects (e.g., arterial pressure), we infused drugs into the right renal artery of anesthetized rats.
MATERIALS AND METHODS
Male Wistar-Kyoto rats (Taconic Farms, Germantown, NY) ranging in age from 9 to 16 wk, on a regular Purina rat chow diet, were used. Food but not water was withheld 24 h before the study. The rats were anesthetized with pentobarbital sodium (50 mg/kg body wt ip), placed on a heated table to maintain rectal temperature between 36 and 37°C, and tracheotomized (PE-240). Anesthesia was maintained by the infusion of pentobarbital sodium at 0.8 mg · 100 g body wt Ϫ1 ·h Ϫ1 (10) . Catheters (PE-50) were placed into the external jugular and femoral veins and left carotid artery. Systemic arterial pressure was monitored electronically using Cardiomax II (Columbus Instruments, Columbus, OH). Laparotomy was performed, and both the right and left ureters were catheterized (PE-10). The right renal artery was exposed, and the right suprarenal artery (which originates from the right renal artery) was catheterized (PE-10 heat stretched to 180 µm) (10) . After a Transonic Systems flow probe was secured around the right renal artery (Transonic Systems, Ithaca, NY), the abdomen was closed with surgical clips. The duration of these surgical procedures was ϳ60 min. Fluid losses during surgery were replaced with 5% albumin at 1% body weight over 30 min. For the determination of GFR, the animals received an intravenous infusion of normal saline containing [ 14 C]inulin (0.01 mCi/10 ml infusate; NEN, Boston, MA) at a rate of 5 ml/100 g body wt for 30 min, followed by a rate of 0.8 ml · 100 g body wt Ϫ1 ·h Ϫ1 until the end of the experiment. After an equilibration period of 120 min, 40-min urine collections for clearance determinations were begun and eight collections were obtained.
Studies on Renal Function In Vivo
Control group. In the control group, normal saline, the vehicle, was infused alone into the right suprarenal artery at a rate of 40 µl/h for eight collection periods. The rates for both intravenous and intrarenal arterial infusions were the same in all groups.
Z-1046 group. In preliminary studies, after two baseline periods, this group received the D 1 /D 2 agonist Z-1046 at a dose of 0.03 µg · kg Ϫ1 · min Ϫ1 (period 3), 0.30 µg · kg Ϫ1 · min Ϫ1 (period 4), and 3.0 µg · kg Ϫ1 · min Ϫ1 (period 5). Thereafter, the infusate was changed to the vehicle (periods 6-8, recovery periods). After establishing an intrarenal dose of Z-1046 that produced a diuresis and natriuresis, we determined the dopamine receptor involved in subsequent studies. In these studies, after two baseline periods, Z-1046 was infused at 2 µg·kg Ϫ1 · min Ϫ1 for three periods followed by two recovery periods. All infusions were given at a rate of 40 µl/h. To account for the dead space in the renal arterial catheter, we changed the infusate 10 min before each period. Fig. 1 . Effect of saline (s, n ϭ 6), preferential D 2 -like agonist Z-1046 alone (m, 2 µg, n ϭ 10), D 1 -like antagonist SCH-23390 alone (q, 120 ng, n ϭ 7), and D 2 -like antagonist domperidone alone (o, 1 µg, n ϭ 9) or in combination (domperidone ϩ Z-1046, k, n ϭ 6; SCH-23390 ϩ Z-1046, ϩ, n ϭ 5) on urine flow (V) rate in anesthetized saline-loaded Wistar-Kyoto rats. All drugs were infused into 1 renal artery to minimize confounding systemic effects, as described in MATERIALS AND METHODS. Periods over which each drug was infused are shown as lines at top. Z-1046 (2 µg · kg Ϫ1 · min Ϫ1 ) by itself increased V, and SCH-23390 (120 ng · 300 g body wt Ϫ1 · min Ϫ1 ) by itself decreased V, whereas domperidone (1 µg · kg Ϫ1 · min Ϫ1 ) by itself was without effect. Increase in V due to Z-1046 was no longer evident when domperidone or SCH-23390 was combined with Z-1046. Data are means Ϯ SE. * P Ͻ 0.05 vs. baseline period (1) or recovery (6) (7) (8) Fig. 4 ). 5) . Thereafter, the infusate was changed to the vehicle (periods 6-8, recovery periods). This dose of SCH-23390 has been shown to be effective in blocking the diuretic and natriuretic effect of up to 120 ng · 300 g body wt Ϫ1 · min Ϫ1 of the D 1 -like agonist SKF-38393 in anesthetized rats (12) .
Z-1046 and SCH-23390 group. After a baseline period, this group received the D 1 antagonist SCH-23390 at 120 ng · 300 g body wt Ϫ1 · min Ϫ1 for four periods (periods 2-5). From periods 3 to 6, Z-1046 was infused at the same rate as described for the Z-1046 group. Thereafter, the infusate was changed to the vehicle (periods 7 and 8, recovery periods).
Domperidone group. After a baseline period, this group received the D 2 antagonist domperidone at 1 µg · kg body wt Ϫ1 · min Ϫ1 for four periods (periods 2-5). Thereafter, the infusate was changed to the vehicle (periods 6-8, recovery periods).
Z-1046 and domperidone group. After a baseline period, this group received the D 1 antagonist domperidone at 1 µg · kg body wt Ϫ1 · min Ϫ1 for four periods (periods 2-5). From periods 3 to 6, Z-1046 was infused at 2 µg · kg Ϫ1 · min Ϫ1 as described for the Z-1046 group. Thereafter, the infusate was changed to the vehicle (periods 7 and 8, recovery periods).
Blood samples were obtained before the first collection period, before the fifth collection period, and at the end of the experiment. Radioactivity and sodium and potassium concentrations were assayed in the blood and urine samples.
At the conclusion of the experiment, the position of the intrarenal arterial catheter was verified with lissamine green infusion.
The rats were killed by an overdose of pentobarbital sodium (100 mg/kg body wt). The kidneys were removed, blotted, and weighed for calculation of corrected GFR. Withingroup comparisons were made using ANOVA for repeated measures (ANVR) or paired t-test with Bonferroni correction, and among-group comparisons were made using one-way ANOVA. Scheffé's test was used post hoc in both instances. When the left and right kidney were being compared, a paired t-test was used. P Ͻ 0.05 was considered significant. Table 1 shows that the intrarenal arterial infusion of the vehicle into the right kidney had no effect on mean arterial pressure (MAP), RBF, GFR, V, U Na V, or FE Na .
RESULTS

Effect of Vehicle on Renal Function
Dose Response Effect of Z-1046 on Renal Function
Z-1046 (0.03, 0.3, and 3.0 µg · kg Ϫ1 · min Ϫ1 ; n ϭ 8, with each dose administered for 40 min into the right kidney) increased RBF, V, U Na V, and FE Na without affecting GFR; the changes were significant at the dose Fig. 2 . Effect of saline (s, n ϭ 6), preferential D 2 -like agonist Z-1046 alone (m, 2 µg, n ϭ 10), D 1 -like antagonist SCH-23390 alone (q, 120 ng, n ϭ 7), and D 2 -like antagonist domperidone alone (o, 1 µg, n ϭ 9) or in combination (domperidone ϩ Z-1046, k, n ϭ 6; SCH-23390 ϩ Z-1046, ϩ, n ϭ 5) on sodium excretion (U Na V) in anesthetized saline-loaded Wistar-Kyoto rats. All drugs were infused into 1 renal artery to minimize confounding systemic effects, as described in MATERIALS AND METHODS. Periods over which each drug was infused are shown as lines at top. Z-1046 (2 µg · kg Ϫ1 · min Ϫ1 ) by itself increased U Na V, and SCH-23390 (120 ng · 300 g body wt Ϫ1 · min Ϫ1 ) by itself decreased U Na V, whereas domperidone (1 µg · kg Ϫ1 · min Ϫ1 ) by itself was without effect. Increase in U Na V due to Z-1046 was no longer evident when domperidone or SCH-23390 was combined with Z-1046. Data are means Ϯ SE. * P Ͻ 0.05 vs. baseline period (1) or recovery (6-8) by ANVR and Scheffé's test. a P Ͻ 0.05 vs. others except domperidone and Z-1046 by ANOVA and Scheffé's test. Fig. 3 . Effect of saline (s, n ϭ 6), preferential D 2 -like agonist Z-1046 alone (m, 2 µg, n ϭ 10), D 1 -like antagonist SCH-23390 alone (q, 120 ng, n ϭ 7), and D 2 -like antagonist domperidone alone (o, 1 µg, n ϭ 9) or in combination (domperidone ϩ Z-1046, k, n ϭ 6; SCH-23390 ϩ Z-1046, ϩ, n ϭ 5) on fractional sodium excretion (FE Na ) in anesthetized saline-loaded Wistar-Kyoto rats. All drugs were infused into 1 renal artery to minimize confounding systemic effects, as described in MATERIALS AND METHODS. Periods over which each drug was infused are shown as lines at top. Z-1046 (2 µg · kg Ϫ1 · min Ϫ1 ) by itself increased FE Na , and SCH-23390 (120 ng · 300 g body wt Ϫ1 · min Ϫ1 ) by itself decreased FE Na , whereas domperidone (1 µg · kg Ϫ1 · min Ϫ1 ) by itself was without effect. Increase in FE Na due to Z-1046 was no longer evident when domperidone or SCH-23390 was combined with Z-1046. There was a tendency for FE Na to overshoot after discontinuation of SCH-23390 both alone and in combined Z-1046 and SCH-23390 infusion, but changes were not significant. Data are means Ϯ SE. * P Ͻ 0.05 vs. baseline period (1) or recovery (6) (7) (8) (Table 2 ). Significant diuresis and natriuresis also occurred in the contralateral noninfused left kidney, indicating recirculation (data not shown), although neither MAP (Table 2 ) nor heart rate (data not shown) was affected by the drug infusion.
To determine the dopamine receptor subtype involved in the renal hemodynamic and functional effects of Z-1046, we studied the intrarenal effects of Z-1046 infused at 2 µg · kg Ϫ1 · min Ϫ1 (Table 3) . Z-1046 increased V (Fig. 1) , U Na V (Fig. 2) , and FE Na (Fig. 3) ; the changes were significant after 80 min of Z-1046 infusion. Z-1046 also increased RBF in absolute terms and as percent change from the baseline period (Fig. 4) ; a percent change in RBF is shown because the baseline RBF varied from group to group. GFR significantly increased after 80 but not after 120 minutes of infusion (Fig. 5) . There was recirculation of the Z-1046 affecting renal function in the contralateral noninfused left kidney, but neither MAP nor heart rate was affected by Z-1046 infusion (data not shown).
Effect of D 2 -Like Blockade on Z-1046
Domperidone, a D 2 -like antagonist, infused by itself at 1.0 µg · kg Ϫ1 · min Ϫ1 did not affect V, U Na V, FE Na , RBF, or GFR in the infused (Table 4 and Figs. 1-5 ) or noninfused kidney (data not shown). To determine further if a D 2 -like antagonist can indeed block the diuretic and natriuretic effect of Z-1046, domperidone was coadministered with Z-1046 (2.0 µg · kg Ϫ1 · min Ϫ1 ). In this setting, the ability of Z-1046 to increase V, U Na V, and FE Na was no longer evident (Table 5 and Figs. 1-3 ). Thus D 2 -like receptors are important in the diuretic and natriuretic effect of Z-1046. In contrast, the increase in RBF after Z-1046 (2 µg · kg Ϫ1 · min Ϫ1 ) was enhanced by domperidone (Table 5 and Fig. 4) . These results suggest that Z-1046, via D 2 -like receptors, has a vasoconstrictor effect (19, 38) .
Effect of D 1 -Like Antagonist
Infusion of the D 1 -like antagonist SCH-23390 alone at 120 ng · 300 g body wt Ϫ1 · min Ϫ1 decreased V, U Na V, and FE Na after 40 min of infusion without affecting RBF and GFR (Table 6 and Figs. 1-5 ). The ability of SCH-23390 to decrease water and sodium excretion is in agreement with previous studies, supporting the hypothesis that D 1 -like receptors are important in the regulation of sodium excretion in volume-expanded animals (12, 23) .
SCH-23390 also blocked the increases in V, U Na V, and FE Na induced by Z-1046 (2 µg · kg body wt Ϫ1 · min Ϫ1 ; Fig. 4 . Effect of saline (s, n ϭ 6), preferential D 2 -like agonist Z-1046 alone (m, 2 µg, n ϭ 7), D 1 -like antagonist SCH-23390 alone (q, 120 ng, n ϭ 7), and D 2 -like antagonist domperidone alone (o, 1 µg, n ϭ 6) or in combination (domperidone ϩ Z-1046, k, n ϭ 4; SCH-23390 ϩ Z-1046, ϩ, n ϭ 3) on renal blood flow (RBF) in anesthetized saline-loaded Wistar-Kyoto rats. All drugs were infused into 1 renal artery to minimize confounding systemic effects, as described in MATERIALS AND METHODS. Periods over which each drug was infused are shown as lines at top. Because baseline RBF varied from group to group, results are expressed as percent change from baseline. Z-1046 (2 µg · kg Ϫ1 · min Ϫ1 ) by itself increased RBF, and neither SCH-23390 (120 ng · 300 g body wt Ϫ1 · min Ϫ1 ) nor domperidone (1 µg · kg Ϫ1 · min Ϫ1 ) infused alone had any effect. Increase in RBF due to Z-1046 was no longer evident when SCH-23390 was combined with Z-1046. In contrast, renal vasodilatory effect of Z-1046 was enhanced in presence of domperidone. Data are means Ϯ SE. * P Ͻ 0.05 vs. baseline period (2) by ANVR and Scheffé's test, # P Ͻ 0.05 vs. other groups by ANOVA and Scheffé's test, a P Ͻ 0.05 vs. others except domperidone, c P Ͻ 0.05 vs. others except Z-1046, d P Ͻ 0.05 Z-1046 vs. others except combination of domperidone and Z-1046 infusion by ANOVA and Scheffé's test. Fig. 5 . Effect of saline (s, n ϭ 6), preferential D 2 -like agonist Z-1046 alone (m, 2 µg, n ϭ 10), D 1 -like antagonist SCH-23390 alone (q, 120 ng, n ϭ 7), and D 2 -like antagonist domperidone alone (o, 1 µg, n ϭ 9) or in combination (domperidone ϩ Z-1046, k, n ϭ 6; SCH-23390 ϩ Z-1046, ϩ, n ϭ 5) on glomerular filtration rate (GFR) in anesthetized saline-loaded Wistar-Kyoto rats. All drugs were infused into 1 renal artery to minimize confounding systemic effects, as described in MATERIALS AND METHODS. Periods over which each drug was infused are shown as lines at top. Z-1046 (2 µg · kg Ϫ1 · min Ϫ1 ) by itself transiently increased GFR, and neither SCH-23390 (120 ng · 300 g body wt Ϫ1 · min Ϫ1 ) nor domperidone (1 µg · kg Ϫ1 · min Ϫ1 ) infused alone had any effect. Transient increase in GFR due to Z-1046 was no longer evident when SCH-23390 was combined with Z-1046. Data are means Ϯ SE. Table 7 and Figs. 1-3) . Moreover, SCH-23390 also blocked the ability of Z-1046 to increase RBF and GFR (Table 7 and Figs. 4 and 5) . These studies suggest that D 1 -like receptors are involved in the hemodynamic, diuretic, and natriuretic effects of Z-1046.
DISCUSSION
These studies show that Z-1046, a dopamine receptor agonist with the rank-order potency
, increases RBF, GFR, V, and sodium excretion in a dose-dependent manner (34) . These changes are independent of perfusion pressure. However, the effects of Z-1046 on renal hemodynamics and GFR can be dissociated from its effects on V and sodium excretion. Thus the diuretic and natriuretic effects of Z-1046 occur only during the infusion periods (Figs. 1-3 , periods [2] [3] [4] [5] , whereas the renal vasodilatory effect of Z-1046 persists for several hours thereafter. These studies suggest that Z-1046 may have direct effects on the renal tubule. D 1 -and D 2 -like receptors in the kidney are known to influence renal hemodynamics. In vivo, D 1 -like receptor occupancy in renal resistance vessels leads to vasodilation that becomes more evident under sodium-replete conditions (14, 31) . The effect of D 2 -like receptors on renal hemodynamics is not as straightforward as with D 1 -like receptors. As with D 1 -like receptors, the effect is influenced by sodium balance (5) . In anesthetized hydropenic rats, quinpirole also increases RBF via D 2 -like receptors (35) . Because sympathetic nervous system activity is increased in hydropenia, stimulation of D 2 -like presynaptic receptors in renal nerves could lead to an increase in RBF (see references in Ref. 23 ). In the current studies in anesthetized rats acutely loaded with saline at 5% of body wt, the D 2 agonist domperidone by itself has no effect on renal hemodynamics, GFR, V, or sodium excretion. Z-1046, which has a higher affinity to D 2 -like than to D 1 -like receptors, increased RBF. The renal vasodilatory effect of Z-1046 at a dose of 2 µg · kg Ϫ1 · min Ϫ1 in volume-expanded rats was mediated by D 1 -like rather than D 2 -like receptors. However, the increase in RBF after Z-1046 (2 µg·kg Ϫ1 · min Ϫ1 ) was enhanced by domperidone (Fig. 4) . These results suggest that Z-1046, via D 2 -like receptors, has a vasoconstrictor effect (19, 38) . The detection of a vasoconstrictor effect of D 2 -like receptors might have been uncovered by the volume-expanded experimental conditions (5) .
Both D 1 -and D 2 -like receptors in the kidney have also been found to regulate renal sodium handling. The current studies show that intrarenal blockade of D 1 -like receptors in volume-expanded rats decreases sodium transport independent of renal hemodynamics. These observations confirm our previous report and those of others that endogenous renal dopamine, via D 1 -like receptors, exerts a paracrine natriuretic function in volume-expanded states (reviewed in Ref. 23) . Although the D 1 -like receptors are always associated with a diuretic and natriuretic action, the effect of stimulation of D 2 -like receptors, independent of D 1 -like receptors, on sodium excretion has ranged from antinatriuresis to no effect (reviewed in Ref. 23 ). Although V, µl/min U Na V, neq/min FE Na , % bromocriptine has not been found to affect sodium excretion in vivo (40) , it has been reported to increase Na ϩ -K ϩ -ATPase activity in renal proximal tubules in vitro (20) . In anesthetized rats, the addition of a D 2 -like antagonist to the infusion of a D 1 -like antagonist reverses the antinatriuretic effect of the D 1 antagonist (12). This observation is similar to the natriuretic effect of haloperidol in the isolated perfused rat kidney (2) . In vivo, the intrarenal infusion of another D 2 -like agonist, YM-09151, in chronically instrumented conscious dogs on a moderate sodium diet also increases sodium excretion, whereas the infusion of the D 2 -like agonist quinpirole results in a decrease in V and sodium excretion (38, 39) . These studies suggest an antinatriuretic effect of D 2 -like receptors. However, in vitro studies have suggested that a D 2 -like agonist in concert with a D 1 -like agonist could synergistically act to decrease Na ϩ -K ϩ -ATPase and NHE activity in rat renal proximal tubules and brain striatal cells (3, 4, 33, 36) and inhibit sodium-phosphate cotransport in opossum kidney cells (29) . A synergism between the D 1A and the D 2 receptor is also evident in LTK Ϫ and CHO cells expressing both dopamine receptor subtypes (30, 42) . However, such synergism has not been demonstrated in vivo. The current studies show that diuretic and natriuretic effects of Z-1046 may also be due to synergism between D 1 -and D 2 -like receptors. However, synergism between D 1 -and D 2 -like receptors may be manifest only under volume expansion. The D 2 -like antagonist domperidone was unable to affect the natriuresis associated with either gludopa or dopamine in the non-volume-expanded state (14, 41) . Investigation of the mechanism of this synergism was not an objective of this study. There are several potential explanations. Prevention of ANG II formation by angiotensin-converting enzyme inhibitors or blockade of ANG II receptors with losartan enhances the natriuretic and diuretic effects of fenoldopam, a D 1 -like agonist (6) . D 2 -like receptors can decrease renin secretion in vivo in rats, and disruption of the D 3 receptor gene in mice causes renin-dependent hypertension (1) .
In summary, we have shown that Z-1046 increases RBF, V, and sodium excretion. The Z-1046-mediated increase in RBF is D 1 -like receptor dependent. In contrast, the Z-1046 inhibition of water and sodium transport is both D 1 -and D 2 -like receptor dependent. 
